Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Rovalpituzumab tesirine

Generic Name: Rovalpituzumab tesirine

Drug Type: Biotech

CAS Number: 1613313-09-9

Unique Ingredient Identifier: P256HB60FF

Overview

Rovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer, among others.

Background

Rovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer, among others.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Long-Term Study of Rovalpituzumab Tesirine

Phase 2

Completed

Posted: 2018/06/01

Sponsor:AbbVie

ID:NCT03543358

Expanded Access to Rovalpituzumab Tesirine

Posted: 2018/04/20

Sponsor:AbbVie

ID:NCT03503890

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Phase 3

Withdrawn

Posted: 2017/11/07

Sponsor:AbbVie

ID:NCT03334487

A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer

Phase 1

Completed

Posted: 2017/03/22

Sponsor:AbbVie

ID:NCT03086239

Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)

Phase 3

Completed

Posted: 2017/02/23

Sponsor:AbbVie

ID:NCT03061812

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

AbbVie Terminates Rova-T Development After $5.8B Stemcentrx Deal Becomes Major R&D Setback

3 months ago

AbbVie's $5.8 billion acquisition of Stemcentrx and its lead candidate Rova-T has ended in failure, with the company terminating the drug's development after multiple late-stage trial disappointments.

AbbVie Diversifies Portfolio with FDA Priority Review for Upadacitinib as Humira Faces Biosimilar Competition

3 months ago

AbbVie's JAK1-selective inhibitor upadacitinib has received FDA Priority Review for moderate to severe rheumatoid arthritis, with potential annual sales projected to reach $3 billion.

FDA Approves Tarlatamab as First DLL3-Targeted Therapy for Small Cell Lung Cancer

3 months ago

Tarlatamab, a first-in-class DLL3 T-cell engager, received FDA accelerated approval in May 2024 for treating relapsed/refractory small cell lung cancer, demonstrating a 40% objective response rate in clinical trials.

FDA Grants Accelerated Approval to Tarlatamab for Previously Treated Extensive-Stage Small Cell Lung Cancer

7 months ago

Tarlatamab (Imdelltra) receives accelerated FDA approval for extensive-stage small cell lung cancer (SCLC) post-platinum-based chemotherapy.

DLL3-Targeted Therapies Show Promise in Neuroendocrine Prostate Cancer

8 months ago

Delta-like ligand 3 (DLL3) is emerging as a potential therapeutic target for aggressive neuroendocrine prostate cancer, which often develops resistance to standard treatments.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy